Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.32 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 4/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22428387 | 0.82 | RXRA (0.33) | — | |
| SCHEMBL23105268 | 0.79 | ALDH1A1 (0.35) | ALDH1A3ACACBALDH1A1SMN1; SMN2POLB | |
| SCHEMBL12896071 | 0.78 | ALDH1A3 (0.35) | ALDH1A3FGFR1KMT2ASYKPARP10 | |
| SCHEMBL12191929 | 0.78 | APLNR (0.37) | ALDH1A1APLNR | |
| SCHEMBL18484467 | 0.76 | KMT2A (0.38) | ALDH1A3KMT2ASYKPARP10ACACB | |
| SCHEMBL19493806 | 0.76 | ALDH1A3 (0.34) | ALDH1A3FGFR1KMT2ASYKPARP10 | |
| SCHEMBL22504198 | 0.76 | APLNR (0.31) | APLNR | |
| SCHEMBL24326416 | 0.76 | ALDH1A3 (0.34) | ALDH1A3KMT2ASYKPARP10ACACB | |
| SCHEMBL9369865 | 0.76 | TP53 (0.46) | ALDH1A3KMT2ASYKPARP10MAP4K4 | |
| SCHEMBL355299 | 0.76 | MAP4K4 (0.38) | ALDH1A3KMT2ASYKMAP4K4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773091-B2 | 6-5 fused rings as C5a inhibitors | CHEMOCENTRYX, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773091-B2 | 6-5 fused rings as C5a inhibitors | CHEMOCENTRYX, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| EP-3728216-B1 | PYRAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-06 | — | — | EP | disclosed |
| US-11697646-B2 | Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-07-11 | — | — | US | disclosed |
| US-11697646-B2 | Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-07-11 | — | — | US | disclosed |
| EP-3728242-B1 | CYCLOHEXYL ACID ISOXAZOLE AZOLES AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-03-01 | — | — | EP | disclosed |
| US-11384079-B2 | 6-5 fused rings as C5a inhibitors | CHEMOCENTRYX, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| EP-3727589-B1 | CYCLOHEXYL ACID PYRAZOLE AZOLES AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2022-06-29 | — | — | EP | disclosed |
| US-11352345-B2 | Cyclohexyl acid pyrazole azoles as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-06-07 | — | — | US | disclosed |
| US-11319309-B2 | Cyclohexyl acid isoxazole azines as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210230143-A1 | CYCLOHEXYL ACID TRIAZOLE AZINES AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-07-29 | — | — | US | disclosed |
| US-20210087178-A1 | CYCLOHEXYL ACID PYRAZOLE AZINES AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-03-25 | — | — | US | disclosed |
| US-20210078982-A1 | CYCLOHEXYL ACID PYRAZOLE AZOLES AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-03-18 | — | — | US | disclosed |
| US-20200347049-A1 | 6-5 FUSED RINGS AS C5a INHIBITORS | CHEMOCENTRYX, INC. | 2020-11-05 | — | — | US | disclosed |
| US-20200317662-A1 | CYCLOHEXYL ACID ISOXAZOLE AZOLES AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-10-08 | — | — | US | disclosed |
| US-20200317655-A1 | ISOXAZOLE O-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-10-08 | — | — | US | disclosed |
| US-20200308148-A1 | PYRAZOLE O-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-10-01 | — | — | US | disclosed |
| US-10662172-B2 | Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-05-26 | — | — | US | disclosed |
| US-10562896-B2 | 6-5 fused rings as C5a inhibitors | CHEMOCENTRYX, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190185446-A1 | TRIAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347049-A1 | 6-5 FUSED RINGS AS C5a INHIBITORS | C5AR1, C5AR2, C3AR1 | ALDH1A3 3643/4885FGFR1 3438/4885KMT2A 4819/4885 |
| US-20210078982-A1 | CYCLOHEXYL ACID PYRAZOLE AZOLES AS LPA ANTAGONISTS | LPAR1, LPAR3, LPAR2 | ALDH1A3 2078/4885FGFR1 84/4885KMT2A 2722/4885 |
| US-11319309-B2 | Cyclohexyl acid isoxazole azines as LPA antagonists | LPAR1, LPAR2, LPAR5 | ALDH1A3 2110/4885FGFR1 195/4885KMT2A 3197/4885 |
| US-20210230143-A1 | CYCLOHEXYL ACID TRIAZOLE AZINES AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | ALDH1A3 2228/4885FGFR1 93/4885KMT2A 1913/4885 |
| US-11773091-B2 | 6-5 fused rings as C5a inhibitors | C5AR1, C5AR2, C3AR1 | ALDH1A3 3643/4885FGFR1 3438/4885KMT2A 4819/4885 |
| US-11384079-B2 | 6-5 fused rings as C5a inhibitors | C5AR1, C5AR2, C3AR1 | ALDH1A3 3643/4885FGFR1 3438/4885KMT2A 4819/4885 |
| US-20190185446-A1 | TRIAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | ALDH1A3 2794/4885FGFR1 103/4885KMT2A 1795/4885 |
| US-20210087178-A1 | CYCLOHEXYL ACID PYRAZOLE AZINES AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | ALDH1A3 2329/4885FGFR1 78/4885KMT2A 2889/4885 |
| US-10662172-B2 | Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists | LPAR3, LPAR1, LPAR2 | ALDH1A3 2794/4885FGFR1 103/4885KMT2A 1795/4885 |
| US-20200308148-A1 | PYRAZOLE O-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | ALDH1A3 2714/4885FGFR1 89/4885KMT2A 2297/4885 |
| US-20200317662-A1 | CYCLOHEXYL ACID ISOXAZOLE AZOLES AS LPA ANTAGONISTS | LPAR1, LPAR2, LPAR3 | ALDH1A3 1751/4885FGFR1 241/4885KMT2A 2720/4885 |
| US-10562896-B2 | 6-5 fused rings as C5a inhibitors | C5AR1, C5AR2, C3AR1 | ALDH1A3 3643/4885FGFR1 3438/4885KMT2A 4819/4885 |
| US-11697646-B2 | Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists | LPAR3, LPAR1, LPAR2 | ALDH1A3 2794/4885FGFR1 103/4885KMT2A 1795/4885 |
| US-20200317655-A1 | ISOXAZOLE O-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR4, LPAR6 | ALDH1A3 1917/4885FGFR1 1214/4885KMT2A 3510/4885 |
| US-11352345-B2 | Cyclohexyl acid pyrazole azoles as LPA antagonists | LPAR1, LPAR3, LPAR2 | ALDH1A3 2078/4885FGFR1 84/4885KMT2A 2722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.